Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Major Histocompatibility Complex (MHC) class I and II antigen presentation machinery is a coordinated cellular system responsible for processing intracellular and extracellular proteins into peptide fragments and displaying them on the cell surface. This machinery is fundamental to adaptive immunity, enabling CD8+ cytotoxic T cells and CD4+ helper T cells to survey the proteome for signs of infection, malignancy, or foreign grafts. Key components of this pathway include the immunoproteasome, the Transporter associated with Antigen Processing (TAP), and the peptide-loading complex.
In oncology, many tumors downregulate or mutate components of this machinery to evade immune detection, contributing to resistance against immune checkpoint inhibitors. Conversely, therapeutic strategies aim to restore or enhance its function using epigenetic modulators (such as HDAC or EZH2 inhibitors) or small molecules (like harmine derivatives) to increase tumor immunogenicity. In transplantation medicine, ex vivo gene therapies (such as ALG-115) are being developed to selectively downregulate this machinery in donor organs, reducing graft immunogenicity and preventing rejection without requiring lifelong systemic immunosuppression.
Modulation of antigen presentation through epigenetic upregulation (e.g., HDAC or EZH2 inhibition), proteasomal inhibition, or ex vivo gene silencing to alter the cell-surface expression of peptide-MHC complexes.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major Histocompatibility Complex Class I and II Antigen Presentation Machinery (MHC I/II APM).